AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 279: H970-H975, 2000;
0363-6135/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (60)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lentz, S. R.
Right arrow Articles by Faraci, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lentz, S. R.
Right arrow Articles by Faraci, F. M.
Vol. 279, Issue 3, H970-H975, September 2000

Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta -synthase-deficient mice

Steven R. Lentz1,2, Rochelle A. Erger1, Sanjana Dayal2, Nobuyo Maeda4, M. René Malinow5, Donald D. Heistad1,2,3, and Frank M. Faraci2,3

1 Veterans Affairs Medical Center, Iowa City 52246; Departments of 2 Internal Medicine and 3 Pharmacology, University of Iowa College of Medicine, Iowa City, Iowa 52242; 4 Department of Pathology, University of North Carolina, Chapel Hill, North Carolina 27599; and 5 Oregon Regional Primate Research Center, Beaverton, Oregon 97006


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Hyperhomocysteinemia is a risk factor for stroke, myocardial infarction, and venous thrombosis. Moderate hyperhomocysteinemia is associated with impaired endothelial function, but the mechanisms responsible for endothelial dysfunction in hyperhomocysteinemia are poorly understood. We have used genetic and dietary approaches to produce hyperhomocysteinemia in mice. Heterozygous cystathionine beta -synthase-deficient mice (CBS +/-), which have a selective defect in homocysteine transsulfuration, and wild-type (CBS +/+) littermates were fed either a control diet or a diet that is relatively deficient in folic acid for 6 wk. Plasma total homocysteine was 5.3 ± 0.7 µM in CBS +/+ mice and 6.4 ± 0.6 µM in CBS +/- mice (P = 0.3) given the control diet. Plasma total homocysteine was 11.6 ± 4.5 µM in CBS +/+ mice and 25.1 ± 3.2 µM in CBS +/- mice (P = 0.004) given a low-folate diet. In mice fed the control diet, relaxation of aortic rings in response to the endothelium-dependent vasodilator acetylcholine did not differ significantly between CBS +/+ mice and CBS +/- mice. In contrast, in mice fed a low-folate diet, maximal relaxation to acetylcholine was markedly impaired in CBS +/- mice (58 ± 9%) compared with CBS +/+ mice (84 ± 4%) (P = 0.01). No differences in relaxation to the endothelium-independent vasodilator sodium nitroprusside were observed among the four groups of mice. These data indicate that CBS-deficient mice are predisposed to hyperhomocysteinemia during dietary folate deficiency, and moderate hyperhomocysteinemia is associated with marked impairment of endothelial function in mice.

acetylcholine; atherosclerosis; endothelium; homocysteine; thrombomodulin


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

HYPERHOMOCYSTEINEMIA is associated with increased risk for stroke, myocardial infarction, and venous thrombosis (3, 7, 27). Previous studies in humans and nonhuman primates have demonstrated that experimental moderate hyperhomocysteinemia (plasma total homocysteine concentration of 10-30 µM) produces endothelial dysfunction, including impaired endothelium-dependent vasodilatation (1, 4, 5, 16, 25, 38) and decreased thrombomodulin anticoagulant activity (22, 25). However, the precise mechanisms by which hyperhomocysteinemia predisposes blood vessels to endothelial dysfunction are poorly understood (20).

Several potential mechanisms have been proposed to explain endothelial dysfunction during hyperhomocysteinemia, including direct endothelial injury due to increased oxidative stress (26, 30), homocysteine-induced reductive stress leading to altered gene expression (33), altered cellular methylation (19), and direct effects on coagulation or fibrinolysis (13, 21). Experimental evidence for some of these proposed mechanisms has been obtained from studies of endothelial cells exposed to exogenous homocysteine in vitro, but these mechanisms have not been examined definitively using a physiologically relevant model of hyperhomocysteinemia in vivo.

One approach to examine mechanisms of endothelial dysfunction in vivo is to study effects of hyperhomocysteinemia in genetically altered strains of mice. The first well-characterized genetic model of hyperhomocysteinemia in mice was developed by Watanabe et al. (39), who created a targeted deletion of the cystathionine beta -synthase (CBS) gene by homologous recombination. Because CBS is the rate-limiting enzyme in homocysteine transsulfuration (10), CBS-deficient mice are predisposed to hyperhomocysteinemia. When homozygous CBS-deficient mice (CBS -/-) are fed a standard laboratory diet, they develop markedly elevated levels of plasma total homocysteine (~200 µM), and they also exhibit growth retardation, hepatic dysfunction, and shortened survival. Because of the severity of the phenotype, however, CBS -/- mice may have limited utility for investigation of specific effects of hyperhomocysteinemia on endothelial function. In contrast, heterozygous CBS-deficient mice (CBS +/-) may be a more useful experimental model of hyperhomocysteinemia because they have normal growth and viability despite mildly elevated concentrations of plasma total homocysteine (6-15 µM) (39). Concentrations of plasma total homocysteine in CBS +/- mice are quite similar to those in humans with heterozygous CBS deficiency (31), which suggests that partial genetic impairment of homocysteine transsulfuration produces similar effects on homocysteine metabolism in humans and mice.

CBS +/- mice do not develop spontaneous atherosclerotic or other vascular lesions when fed a normal diet (39), but a recent preliminary report suggests that they may have subtle abnormalities of endothelial vasomotor function (6). It is uncertain, however, whether this genetic model will be useful to dissect mechanisms of endothelial dysfunction in hyperhomocysteinemia. Because homocysteine metabolism is influenced by both genetic and dietary factors (27), we suspected that the vascular phenotype of CBS-deficient mice may vary depending on dietary conditions. Therefore, we tested the hypothesis that CBS +/- mice are predisposed to hyperhomocysteinemia and endothelial dysfunction by dietary folate deficiency, which impairs homocysteine remethylation. Our results demonstrate that dietary folate deficiency elevates plasma total homocysteine concentration and produces marked endothelial dysfunction in CBS +/- mice.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Mice and experimental protocol. To minimize the potential influence of differences in genetic background, CBS-deficient mice (39) were crossbred to C57BL/6J mice (The Jackson Laboratory) for at least eight generations, and comparisons were performed between heterozygous CBS-deficient (CBS +/-) mice and wild-type (CBS +/+) littermates. Genotyping for the targeted CBS allele was performed by polymerase chain reaction (39). At the time of weaning, mice were fed either a control diet that contains 0.75 mg folic acid/100 g (LM-485, Harlan Teklad) or a diet that is relatively deficient in folic acid (0.15 mg/100 g) for 6 wk. The low-folate diet contained succinylsulfathiazole (0.1 mg/100 g) to decrease folate availability from intestinal bacteria. At 9-10 wk of age, mice were euthanized with pentobarbital sodium (75 mg ip), plasma was collected into EDTA (final concentration 5-10 mM) for measurement of total homocysteine and folate, and the thoracic aorta was removed for ex vivo studies. The experimental protocol was approved by the University of Iowa and Veterans Affairs Animal Care and Use Committees.

Vascular responses. After removal of loose connective tissue, the proximal aorta was cut into multiple 3- to 4-mm rings. Rings were suspended in an organ chamber containing oxygenated Krebs buffer maintained at 37°C and connected to a force transducer to measure isometric tension (contraction and relaxation) (2, 25). Contraction dose-response curves were generated by cumulative additions of the thromboxane A2 analog U-46619 (0.03-3 µg/ml). Other rings were contracted submaximally using U-46619, and relaxation dose-response curves were generated by cumulative additions of the endothelium-dependent vasodilator acetylcholine (10-8 to 10-5 M) or the endothelium-independent vasodilator sodium nitroprusside (10-8 to 10-5 M). We have used these methods previously in mouse vessels and demonstrated that responses to acetylcholine are mediated by nitric oxide (2, 9, 18).

Aortic thrombomodulin activity. Thrombomodulin activity (thrombomodulin-dependent activation of protein C) was measured using a modification of a two-stage assay described previously (25). In the first stage, 0.15 µM human protein C (generously provided by Dr. Hans Peter Schwarz, Immuno) and 2.6 nM human thrombin (Enzyme Research Laboratories) were incubated for 30 min at 37°C with rings of proximal thoracic aorta 1.0 mm in length. In the second stage, the amidolytic activity of activated protein C was measured spectrophotometrically using the chromogenic substrate S-2366 (Kabi Pharmacia Hepar). Replicate assays were performed with four to five rings from each aorta. Reference curves were generated using rabbit lung thrombomodulin (American Diagnostica). One unit of activity was defined as the amount of activated protein C generated in the presence of 1.0 nM rabbit thrombomodulin. This assay detects thrombomodulin activity on the luminal endothelium, because denudation of the vessels decreased protein C activation by >90%.

Plasma assays. Plasma total homocysteine concentration was measured by high-performance liquid chromatography and electrochemical detection as described previously (28, 29). Total homocysteine was defined as the amount of homocysteine obtained after treatment of the sample with a reducing agent that converts free and bound disulfides into their respective thiols (32). Hyperhomocysteinemia was defined as the elevation of plasma total homocysteine. Plasma levels of folate were measured by an automated chemiluminescence immunoassay (Chiron Diagnostics ACS:180).

Statistical analysis. Comparisons were performed using the unpaired two-tailed Student's t-test. A value of P < 0.05 was used to define statistical significance. Values are reported as means ± SE.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Experimental hyperhomocysteinemia. Experimental hyperhomocysteinemia was produced by combining dietary folate deficiency with genetic deficiency of CBS. Deficiency of folate was used to limit homocysteine remethylation, and heterozygous CBS deficiency was employed to examine effects of impaired homocysteine transsulfuration (Fig. 1). Beginning at the time of weaning (about 3 wk of age), CBS +/- and CBS +/+ littermates were fed either control diet or low-folate diet for 6-7 wk. In mice fed control diet, plasma total homocysteine concentration did not differ significantly between CBS +/- and CBS +/+ mice (Table 1). In mice fed low-folate diet, plasma total homocysteine concentration was markedly elevated in CBS +/- mice compared with CBS +/+ mice (P = 0.004) (Table 1). Plasma concentrations of folate were ~50% lower in CBS +/+ or CBS +/- mice fed low-folate diet compared with CBS +/+ or CBS +/- mice fed control diet (P = 0.001) (Table 1).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Production of hyperhomocysteinemia in mice. Dietary deficiency of folate produces hyperhomocysteinemia by limiting homocysteine remethylation, whereas genetic deficiency of cystathionine beta -synthase (CBS) produces hyperhomocysteinemia by interfering with homocysteine transsulfuration. SAM, S-adenosyl methionine; SAH, S-adenosyl homocysteine.


                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Effect of diet and CBS genotype on plasma concentrations of total homocysteine and folate

Vasomotor responses. The endothelium-dependent vasodilator acetylcholine and the endothelium-independent vasodilator nitroprusside each produced dose-dependent relaxation of aortic rings from all mice. In mice fed control diet, no differences in relaxation to acetylcholine were observed between CBS +/+ and CBS +/- mice (Fig. 2A). Maximal relaxation to the highest dose of acetylcholine was 81 ± 4% in CBS +/+ mice and 75 ± 5% in CBS +/- mice (P = 0.4). Similarly, no differences in relaxation to nitroprusside (Fig. 3B) or contraction to the thromboxane A2 analog U-46619 (Fig. 2C) were observed between CBS +/+ and CBS +/- mice fed control diet.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Vasomotor responses of aortas from wild-type (CBS +/+) mice (filled symbols; n = 9) or heterozygous CBS-deficient (CBS +/-) mice (open symbols; n = 14) fed control diet. A: relaxation to acetylcholine. B: relaxation to sodium nitroprusside. C: contraction to the thromboxane A2 analog U-46619. Four rings were studied from each animal.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Vasomotor responses of aortas from CBS +/+ mice (filled symbols; n = 9) or CBS +/- mice (open symbols; n = 8) fed low-folate diet. A: relaxation to acetylcholine. B: relaxation to nitroprusside. C: contraction to the thromboxane A2 analog U-46619. *P < 0.05 vs. CBS +/+ mice. Four rings were studied from each animal.

In mice fed low-folate diet, relaxation to acetylcholine was markedly impaired in CBS +/- mice compared with CBS +/+ mice (Fig. 3A). Maximal relaxation to acetylcholine was 58 ± 9% in CBS +/- mice compared with a relaxation of 84 ± 4% in CBS +/+ mice (P = 0.01). Relaxation to nitroprusside did not differ significantly between CBS +/+ and CBS +/- mice fed low-folate diet (Fig. 3B), although maximal relaxation to nitroprusside tended to be lower in CBS +/- mice than in CBS +/+ mice (P = 0.14). No differences in contraction to U-46619 were observed between CBS +/+ and CBS +/- mice fed low-folate diet (Fig. 3C).

Aortic thrombomodulin activity. Previous studies in monkeys suggested that diet-induced hyperhomocysteinemia was associated with impaired thrombomodulin-dependent activation of anticoagulant protein C in the aorta and carotid artery (25). Therefore, we measured thrombomodulin activity ex vivo in aortas obtained from mice fed control or low-folate diets. No differences in aortic thrombomodulin activity were observed between CBS +/+ and CBS +/- mice fed either control or low-folate diets (Fig. 4).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   Aortic thrombomodulin activity. Thrombomodulin-dependent activation of protein C in proximal aorta was measured in CBS +/+ mice (open bars; n = 9) and CBS +/- mice (hatched bars; n = 8-14) fed either control diet or low-folate diet. Four to five rings were studied from each animal.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this study, we have combined genetic and dietary approaches to produce moderate hyperhomocysteinemia in mice. We found that dietary folate deficiency produced a greater elevation in plasma total homocysteine concentration in CBS +/- mice than in CBS +/+ mice. Endothelial vasomotor dysfunction was observed only in mice with a combined defect in homocysteine remethylation (produced by dietary folate deficiency) and homocysteine transsulfuration (produced by heterozygous deficiency of CBS).

The mean plasma total homocysteine concentration in CBS +/- mice fed the low-folate diet was 25 µM, which is similar to plasma total homocysteine levels obtained after oral methionine loading in humans (12). Several recent studies have demonstrated that methionine loading produces acute impairment of endothelium-dependent relaxation of conduit or resistance vessels in human subjects (1, 4, 5, 16, 38). In each of these studies, acute impairment of endothelial function was detected within 2-8 h after ingestion of methionine, which increased plasma total homocysteine concentrations to 20-30 µM. Our observation that responses to the endothelium-dependent vasodilator acetylcholine were impaired in CBS +/- mice that were fed the low-folate diet indicates that experimental hyperhomocysteinemia also produces adverse effects on endothelial function in mice. These findings are consistent with our previous studies in which endothelial vasomotor dysfunction was detected in cynomolgus monkeys with diet-induced hyperhomocysteinemia (25). Because impaired vasomotor responses were observed only in the group of mice with the highest levels of plasma total homocysteine, it cannot be determined from these data whether the CBS +/- genotype sensitizes to vascular function independently of its effects on plasma total homocysteine concentration.

In contrast to the marked endothelial vasomotor dysfunction observed in CBS +/- mice fed low-folate diet, no impairment of endothelial function was detected in CBS +/+ mice fed low-folate diet, even though these mice had mildly elevated concentrations of plasma total homocysteine (~12 µM). This finding in mice differs somewhat from previous findings in cynomolgus monkeys, in which endothelial dysfunction was detected in the presence of very mild elevation of plasma concentrations of total homocysteine (~11 µM) (25). Thus it appears that higher concentrations of plasma total homocysteine may be required to produce endothelial vasomotor dysfunction in mice than in monkeys. This apparent difference in concentration dependence may be partly due to the fact that fasting homocysteine levels were measured in monkeys, whereas nonfasting levels were measured in mice. It also is possible that the differential sensitivity to hyperhomocysteinemia between monkeys and mice is due to species-specific differences in antioxidant mechanisms (35) or other mechanisms that regulate endothelium-dependent relaxation. Despite these differences in concentration dependence, it is clear that endothelial vasomotor dysfunction is a consistent and reproducible consequence of hyperhomocysteinemia in experimental animals and humans. Previous studies using pharmacological approaches and gene-targeting have demonstrated that relaxation of the mouse aorta in response to acetylcholine is mediated by nitric oxide produced by endothelial nitric oxide synthase (15, 17, 18). These ex vivo findings are consistent with earlier observations that homocysteine decreases bioavailability of nitric oxide in cultured endothelial cells (36, 37). In addition to preventing pathological vasoconstriction, endothelium-derived nitric oxide also inhibits platelet aggregation and leukocyte adhesion. Thus decreased bioavailability of nitric oxide is a plausible mechanism for increased risk of thrombosis and atherosclerosis in hyperhomocysteinemia.

If oxidative inactivation of endogenous endothelium-derived nitric oxide is a major mechanism for endothelial dysfunction in experimental hyperhomocysteinemia (26), one might also expect to see abnormal vascular responses to exogenous nitrovasodilators, such as nitroprusside. We observed that CBS +/- and CBS +/+ mice tended to differ in responses to nitroprusside when they were fed the low-folate diet (Fig. 4B). Although this difference did not reach statistical significance, the observation is consistent with previous findings that vasodilator responses to nitroprusside are modestly impaired in monkeys with diet-induced hyperhomocysteinemia or hypercholesterolemia (8, 22, 25). These observations suggest that hyperhomocysteinemia may lead to oxidative inactivation of nitric oxide derived from both exogenous and endogenous sources.

In addition to producing impairment of endothelial vasomotor function, hyperhomocysteinemia may adversely affect anticoagulant properties of endothelium. Thrombomodulin is an endothelial surface protein that functions as a critical cofactor for activation of anticoagulant protein C (24). The thrombomodulin/protein C system and endothelium-dependent regulation of vasomotor tone are two distinct but complementary properties of endothelium that may protect vessels from thrombotic complications of vascular disease. Thrombomodulin-dependent activation of protein C can be inhibited by exogenous homocysteine in cultured human endothelial cells (14, 23, 34), and monkeys with diet-induced hyperhomocysteinemia have decreased thrombomodulin activity in the aorta and carotid artery (25). We did not, however, detect any differences in aortic thrombomodulin activity between CBS +/+ and CBS +/- mice fed either control or low-folate diets. These results imply that human, macaque, and murine thrombomodulin may differ in sensitivity to hyperhomocysteinemia. In this regard, it is noteworthy that human thrombomodulin contains a critical methionine residue that is sensitive to oxidation, which results in loss of thrombomodulin activity (11). Although murine thrombomodulin also contains a methionine residue in this position, it is not known whether its activity is altered by oxidative stress.

In summary, a folate-deficient diet produces hyperhomocysteinemia and impaired endothelial function in heterozygous CBS-deficient mice. Because of the increasing use of transgenic and gene-targeting techniques in mice, the availability of this murine model should facilitate future studies of mechanisms of vascular dysfunction in hyperhomocysteinemia.


    ACKNOWLEDGEMENTS

We thank Kara Brown for technical assistance.


    FOOTNOTES

This work was supported by the Office of Research and Development, Department of Veterans Affairs, National Institutes of Health Grants HL-07344, DK-25295, and NS-24621, and the Roy J. Carver Charitable Trust.

Address for reprint requests and other correspondence: S. R. Lentz, Dept. of Internal Medicine, C303 GH, The Univ. of Iowa, Iowa City, IA 52242 (E-mail: steven-lentz{at}uiowa.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6 December 1999; accepted in final form 21 February 2000.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Bellamy, MF, McDowell IFW, Ramsey MW, Brownlee M, Bones C, Newcombe RG, and Lewis MJ. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 98: 1848-1852, 1998[Abstract/Free Full Text].

2.   Bonthu, S, Heistad DD, Chappell DA, Lamping KG, and Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol 17: 2333-2340, 1997[Abstract/Free Full Text].

3.   Boushey, CJ, Beresford SAA, Omenn GS, and Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057, 1995[Abstract].

4.   Chambers, JC, McGregor A, Jean-Marie J, and Kooner JS. Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 351: 36-37, 1998[ISI][Medline].

5.   Chambers, JC, McGregor A, Jean-Marie J, Obeid OA, and Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 99: 1156-1160, 1999[Abstract/Free Full Text].

6.   Eberhardt, RT, Forgione M, Rudd MA, Trolliet MR, Cap A, and Loscalzo J. Endothelial dysfunction in mice lacking the cystathionine beta -synthase gene (Abstract). Circulation 98: I-44, 1998.

7.   Eikelboom, JW, Lonn E, Genest JJ, Hankey G, and Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131: 363-375, 1999[Abstract/Free Full Text].

8.   Faraci, FM, Orgren K, and Heistad DD. Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys. Stroke 25: 178-182, 1994[Abstract].

9.   Faraci, FM, Sigmund CD, Shesely EG, Maeda N, and Heistad DD. Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase. Am J Physiol Heart Circ Physiol 274: H564-H570, 1998[Abstract/Free Full Text].

10.   Finkelstein, JD. The metabolism of homocysteine-pathways and regulation. Eur J Pediatr 157: S40-S44, 1998.

11.   Glaser, CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang R-J, Lin J-H, Vilander L, Andrews WH, and Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 90: 2565-2573, 1992.

12.   Guttormsen, AB, Mansoor AM, Fiskerstrand T, Ueland PM, and Refsum H. Kinetics of plasma homocysteine in healthy subjects after peroral homocysteine loading. Clin Chem 39: 1390-1397, 1993[Abstract].

13.   Hajjar, KA, Mauri L, Jacovina AT, Zhong FM, Mirza UA, Padovan JC, and Chait BT. Tissue plasminogen activator binding to the annexin II tail domain-direct modulation by homocysteine. J Biol Chem 273: 9987-9993, 1998[Abstract/Free Full Text].

14.   Hayashi, T, Honda G, and Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 79: 2930-2936, 1992[Abstract/Free Full Text].

15.   Huang, PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, and Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239-242, 1995[Medline].

16.   Kanani, P, Sinkey CA, Browning RL, Allaman M, Knapp HR, and Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 100: 1161-1168, 1999[Abstract/Free Full Text].

17.   Kojda, G, Laursen JB, Ramasamy S, Kent JD, Kurz S, Burchfield J, Shesely EG, and Harrison DG. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial cell nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res 42: 206-213, 1999[Abstract/Free Full Text].

18.   Lake-Bruse, KD, Faraci FM, Shesely EG, Meada N, and Heistad DD. Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice. Am J Physiol Heart Circ Physiol 277: H770-H776, 1999[Abstract/Free Full Text].

19.   Lee, ME, and Wang H. Homocysteine and hypomethylation-a novel link to vascular disease. Trends Cardiovasc Med 9: 49-54, 1999[ISI][Medline].

20.   Lentz, SR. Homocysteine and vascular dysfunction. Life Sci 61: 1205-1215, 1997[ISI][Medline].

21.   Lentz, SR. Mechanisms of thrombosis in hyperhomocysteinemia. Curr Opin Hematol 5: 343-349, 1998[Medline].

22.   Lentz, SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Faraci FM, and Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol 17: 2930-2934, 1997[Abstract/Free Full Text].

23.   Lentz, SR, and Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914, 1991.

24.   Lentz, SR, and Sadler JE. The molecular basis of thrombomodulin function. In: Thrombin, Thrombomodulin, and the Control of Hemostasis, edited by Giddings JC.. Austin, TX: Landes, 1994, p. 91-120.

25.   Lentz, SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, and Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98: 24-29, 1996[ISI][Medline].

26.   Loscalzo, J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 98: 5-7, 1996[ISI][Medline].

27.   Malinow, MR, Bostom AG, and Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases-a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99: 178-182, 1999[Free Full Text].

28.   Malinow, MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, and Upson B. Prevalence of hyperhomocyt(e)inemia in patients with peripheral arterial occlusive disease. Circulation 79: 1180-1188, 1989[Abstract/Free Full Text].

29.   Malinow, MR, Sexton G, Averbuch M, Grossman M, Wilson D, and Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis 1: 215-220, 1990.

30.   McCully, KS. Homocysteine and vascular disease. Nat Med 2: 386-389, 1996[ISI][Medline].

31.   Mudd, SH, Levy HL, and Skovby F. Disorders of transsulfuration. In: The Metabolic and Molecular Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, and Valle D.. New York: McGraw-Hill, 1995, p. 1279-1327.

32.   Nygård, O, Vollset SE, Refsum H, Brattstrom L, and Ueland PM. Total homocysteine and cardiovascular disease. J Int Med Res 246: 425-454, 1999.

33.   Outinen, PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, and Austin RC. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 94: 959-967, 1999[Abstract/Free Full Text].

34.   Rodgers, GM, and Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 75: 895-901, 1990[Abstract/Free Full Text].

35.   Shaish, A, George J, Gilburd B, Keren P, Levkovitz H, and Harats D. Dietary beta-carotene and alpha-tocopherol combination does not inhibit atherogenesis in an ApoE-deficient mouse model. Arterioscler Thromb Vasc Biol 19: 1470-1475, 1999[Abstract/Free Full Text].

36.   Stamler, JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, and Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91: 308-318, 1993.

37.   Upchurch, GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, and Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: 17012-17017, 1997[Abstract/Free Full Text].

38.   Usui, M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, and Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inemia: restoration by folic acid. Clin Sci (Lond) 96: 235-239, 1999[Medline].

39.   Watanabe, M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, and Maeda N. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA 92: 1585-1589, 1995[Abstract/Free Full Text].


Am J Physiol Heart Circ Physiol 279(3):H970-H975



This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
T. Kitami, R. Rubio, W. O'Brien, J. Quackenbush, and J. H. Nadeau
Gene-environment interactions reveal a homeostatic role for cholesterol metabolism during dietary folate perturbation in mice
Physiol Genomics, October 8, 2008; 35(2): 182 - 190.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Dayal and S. R. Lentz
Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes
Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1596 - 1605.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Dayal, R. N. Rodionov, E. Arning, T. Bottiglieri, M. Kimoto, D. J. Murry, J. P. Cooke, F. M. Faraci, and S. R. Lentz
Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia
Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H816 - H825.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. C. Looft-Wilson, B. S. Ashley, J. E. Billig, M. R. Wolfert, L. A. Ambrecht, and S. E. Bearden
Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R59 - R66.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. Sontag, V. Nunbhakdi-Craig, J.-M. Sontag, R. Diaz-Arrastia, E. Ogris, S. Dayal, S. R. Lentz, E. Arning, and T. Bottiglieri
Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation
J. Neurosci., March 14, 2007; 27(11): 2751 - 2759.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. Symons, J. C. Rutledge, U. Simonsen, and R. A. Pattathu
Vascular dysfunction produced by hyperhomocysteinemia is more severe in the presence of low folate
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H181 - H191.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. W. Powers, R. E. Gandley, D. L. Lykins, and J. M. Roberts
Moderate Hyperhomocysteinemia Decreases Endothelial-Dependent Vasorelaxation in Pregnant But Not Nonpregnant Mice
Hypertension, September 1, 2004; 44(3): 327 - 333.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
V. Vitvitsky, S. Dayal, S. Stabler, Y. Zhou, H. Wang, S. R. Lentz, and R. Banerjee
Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R39 - R46.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zulli, R. E. Widdop, D. L. Hare, B. F. Buxton, and M. J. Black
High Methionine and Cholesterol Diet Abolishes Endothelial Relaxation
Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1358 - 1363.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
K. Robert, F. Vialard, E. Thiery, K. Toyama, P.-M. Sinet, N. Janel, and J. London
Expression of the Cystathionine {beta} Synthase (CBS) Gene During Mouse Development and Immunolocalization in Adult Brain
J. Histochem. Cytochem., March 1, 2003; 51(3): 363 - 371.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. M. Faraci
Hyperhomocysteinemia: A Million Ways to Lose Control
Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 371 - 373.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. S. Sood, M. J. Hunt, and S. C. Tyagi
Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia
Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L333 - L341.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Ratnam, K. N. Maclean, R. L. Jacobs, M. E. Brosnan, J. P. Kraus, and J. T. Brosnan
Hormonal Regulation of Cystathionine beta -Synthase Expression in Liver
J. Biol. Chem., November 1, 2002; 277(45): 42912 - 42918.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo
Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia
Vascular Medicine, August 1, 2002; 7(3): 227 - 239.
[Abstract] [PDF]


Home page
J. Nutr.Home page
S. F. Choumenkovitch, J. Selhub, P. J. Bagley, N. Maeda, M. R. Nadeau, D. E. Smith, and S.-W. Choi
In the Cystathionine {beta}-Synthase Knockout Mouse, Elevations in Total Plasma Homocysteine Increase Tissue S-Adenosylhomocysteine, but Responses of S-Adenosylmethionine and DNA Methylation Are Tissue Specific
J. Nutr., August 1, 2002; 132(8): 2157 - 2160.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. D. Symons, A. E. Mullick, J. L. Ensunsa, A. A. Ma, and J. C. Rutledge
Hyperhomocysteinemia Evoked by Folate Depletion: Effects on Coronary and Carotid Arterial Function
Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 772 - 780.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Zhou, J. Moller, C. C. Danielsen, J. Bentzon, H. B. Ravn, R. C. Austin, and E. Falk
Dietary Supplementation With Methionine and Homocysteine Promotes Early Atherosclerosis but Not Plaque Rupture in ApoE-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1470 - 1476.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Weiss, Y.-Y. Zhang, S. Heydrick, C. Bierl, and J. Loscalzo
Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction
PNAS, October 23, 2001; 98(22): 12503 - 12508.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (60)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lentz, S. R.
Right arrow Articles by Faraci, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lentz, S. R.
Right arrow Articles by Faraci, F. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online